Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes

Diabetes Care

Volumn 25, Issue 5, 2002, Pages 876-882

  Lindholm, Anders ^a,e   Jensen, Lisbeth B ^a   Home, Philip D ^b   Raskin, Philip ^c   Boehm, Bernhard O ^d   Råstam, Jacob ^a  

^a NOVO NORDISK A S   (Denmark)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF ULM   (Germany)

^e Novo Nordisk Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; HUMAN INSULIN; INSULIN ANTIBODY; INSULIN ASPART; TRACER; ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN; INSULIN, ASP(B28)-;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIOIMMUNOASSAY; TREATMENT OUTCOME; ADULT; AGED; BIOSYNTHESIS; BLOOD; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; AGED; CROSS REACTIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTIBODIES; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036580827     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.5.876     Document Type: Article

References (23)

1. Marshall MO, Heding LG, Villumsen J, Akerblom HK, Baevre H, Dahlquist G, Kjaergaard JJ, Knip M, Lindgren F, Ludvigsson J: Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res 9:169-175, 1988
2. Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB: Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic β-cell function. Diabetes Care 18:1452-1459, 1995
3. Heinemann L, Kapitza C, Starke AAR, Heise T: Time-action profile of the insulin analogue B28Asp. Diabet Med 13:683-684, 1996
4. Home PD, Lindholm A, Hylleberg B, Round P, for the U.K. Insulin Aspart Study Group: Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 21:1904-1909, 1998
5. Lindholm A, McEwen J, Riis A: Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 22:801-805, 1999
6. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MY, Havelund S, Melberg SG, Norris F, Nooris K, Snel L, Sörensen AR, Voigt HO: Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682, 1988
7. Blundell T, Dodson G, Hodgkin D, Mercola D: Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Protein Chem 26:279-402, 1972
8. Kang S, Creagh FM, Peters JR, Brange J, Volund A, Owens DR: Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type 1 diabetic subjects. Diabetes Care 14:571-577, 1991
9. Raskin P, Riis A, Guthrie RA, Jovanovic L, Leiter L: Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23:583-588, 2000
10. Home PD, Lindholm A, Riis A: Insulin aspart versus human insulin in the management of long-term blood glucose control in type 1 diabetes: a randomized controlled trial. Diabet Med 17:762-770, 2000
11. Raskin P, McGill J, Kilo C, Boss AH: Human insulin analog (insulin aspart, IAsp) is comparable to human insulin (HI) in type 2 diabetes (Abstract). Diabetes 48 (Suppl. 1):A355, 1999
12. Boehm B, Home PD, Bott U, Behrend C, Kamp NM, Lindholm A: Premixed insulin aspart 30: control and convenience in type 1 and type 2 diabetes (Abstract). Diabetologia 43 (Suppl. 1):A2000, 2000
13. World Health Organization: Prevention of Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1994 (Tech. Rep. Ser., no. 844), p. 11-13
14. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjorn S, Gammeltoft S: Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488-1495, 1991
15. Solberg HE, Gräsbeck R: Reference values (Review). Adv Clin Chem 27:1-79, 1989
16. Ottesen JL, Nilsson P, Jami J, Weilguny D, Duhrkop M, Bucchini D, Havelund S, Fogh JM: The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37:1178-1185, 1994
17. Haeften TW: Clinical significance of insulin antibodies in insulin-treated diabetic patients (Review). Diabetes Care 12:641-648, 1989
18. Greenbaum CJ, Palmer JP: Insulin antibodies and insulin autoantibodies. Diabet Med 8:97-105, 1991
19. Effros RB: Ageing and the immune system. Novartis Found Symp 235:130-139 [Discussion 139-145, 146-149], 2001
20. Koller E: US New Drug Application Medical Review. FDA. Summary Basis of Approval. Rockville, MD, FDA, 1995
21. Humalog. Clinical and Laboratory Experience: A Comprehensive Monograph. Basingstoke, U.K., Eli Lilly, 1996 (monogr. no. 1)
22. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S: Immunologic effects of insulin lispro [lys(B28), pro(B29)human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 45:1750-1754, 1996
23. Roach P, Varshavsky JA, Gantner K, Anderson JH: Insulin antibody formation during treatment with human insulin or insulin lispro does not affect insulin dose requirements (Abstract). Diabetes 45 (Suppl. 2):261A, 1996